An antibody that protects against respiratory syncytial virus (RSV) works well for one year but possibly not beyond, according to newly published research.
Nirsevimab, the antibody, “may not be effective after 12 months of administration,” Japanese researchers reported in the study, which was published on Nov. 6 by the Journal of Infection.
Sanofi, which manufactures nirsevimab with AstraZeneca, did not respond to a request for comment.
Nirsevimab, a monoclonal antibody, is approved in multiple countries for the prevention of RSV in young children. RSV usually causes mild, cold-like symptoms.
It can trigger severe problems that, in a subset of cases, can result in death. The elderly and young children are particularly susceptible….
Antibody Against RSV Prevents Cases for 1 Year: Study
